WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ELVN

Based on 1 analyst offering 12 month price targets for Enliven Therapeutics Inc.
Min Forecast
$34.00+92.42%
Avg Forecast
$34.00+92.42%
Max Forecast
$34.00+92.42%

Should I buy or sell ELVN stock?

Based on 1 analyst offering ratings for Enliven Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ELVN stock forecasts and price targets.

ELVN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-09

1 of 1

Forecast return on equity

Is ELVN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is ELVN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ELVN revenue forecast

What is ELVN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$4.3M
Avg 2 year Forecast
$114.4M
Avg 3 year Forecast
$393.2M

ELVN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELVN$17.67$34.00+92.42%Strong Buy
PLRX$12.19$46.67+282.83%Buy
IRON$30.02$69.60+131.85%Buy
RGNX$16.11$40.38+150.62%Strong Buy
PRTC$26.94N/AN/A
View Top Biotech Stocks

Enliven Therapeutics Stock Forecast FAQ

Is Enliven Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ELVN) stock is to Strong Buy ELVN stock.

Out of 1 analyst, 1 (100%) are recommending ELVN as a Strong Buy, 0 (0%) are recommending ELVN as a Buy, 0 (0%) are recommending ELVN as a Hold, 0 (0%) are recommending ELVN as a Sell, and 0 (0%) are recommending ELVN as a Strong Sell.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.

What is ELVN's revenue growth forecast for 2028-2030?

(NASDAQ: ELVN) Enliven Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Enliven Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ELVN's revenue for 2028 to be $176,967,865, with the lowest ELVN revenue forecast at $176,967,865, and the highest ELVN revenue forecast at $176,967,865. On average, 1 Wall Street analysts forecast ELVN's revenue for 2029 to be $4,729,755,624, with the lowest ELVN revenue forecast at $4,729,755,624, and the highest ELVN revenue forecast at $4,729,755,624.

In 2030, ELVN is forecast to generate $16,257,061,950 in revenue, with the lowest revenue forecast at $16,257,061,950 and the highest revenue forecast at $16,257,061,950.

What is ELVN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ELVN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ELVN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ELVN price target, the average ELVN price target is $34.00, with the highest ELVN stock price forecast at $34.00 and the lowest ELVN stock price forecast at $34.00.

The Wall Street analyst predicted that Enliven Therapeutics's share price could reach $34.00 by Apr 9, 2025. The average Enliven Therapeutics stock price prediction forecasts a potential upside of 92.42% from the current ELVN share price of $17.67.

What is ELVN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ELVN) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.